| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0331
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-495 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 |
| filingDate |
2004-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bb439fe0e5bc2e822822d8d0368d580 |
| publicationDate |
2007-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-PI0416305-A |
| titleOfInvention |
selection method, method of determining whether a mammalian patient diagnosed with cancer is likely to benefit from tgf-beta antagonist treatment, bone destruction or loss treatment method, mammalian patient treatment methods and kit comprising a container |
| abstract |
"SELECTION METHOD, METHOD OF DETERMINATION IF A MAMMALIUM DIAGNOSTIC PATIENT PATIENT IS PROVIDED TO BENEFIT FROM TGF-BETA ANTAGONIST, METHOD OF DESTRUCT BODY MATERIAL DESTRUCTION AND MATERIAL DIAGNOSTIC TREATMENT CONTAINER". The present invention relates generally to the selection of possible molecules for the treatment of tumor metastasis and treatment methods using such molecules. Accordingly, the present invention includes a selection method comprising the steps of: (1) administering a series of test substances to a non-human syngeneic immunocompetent animal model containing at least one bone or soft tissue metastasis in the presence or absence of primary tumor; (2) determining the effects of said test substances on bone or soft tissue metastasis and primary tumor growth, if present; and (3) identification of test substance that inhibits the growth of bone or soft tissue metastasis, with no adverse effects on the condition of the primary tumor, if present. |
| priorityDate |
2003-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |